Ventyx Biosciences Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
85
- Stock Symbol
-
VTYX
- Investments
-
2
- Share Price
-
$1.36
- (As of Monday Closing)
Ventyx Biosciences General Information
Description
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Contact Information
Website
www.ventyxbio.comCorporate Office
- 662 Encinitas Boulevard
- Suite 250
- Encinitas, CA 92024
- United States
Corporate Office
- 662 Encinitas Boulevard
- Suite 250
- Encinitas, CA 92024
- United States
Ventyx Biosciences Timeline
Ventyx Biosciences Stock Performance
As of 24-Mar-2025, Ventyx Biosciences’s stock price is $1.36. Its current market cap is $96.7M with 71.1M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.36 | $1.32 | $1.28 - $7.01 | $96.7M | 71.1M | 1.3M | -$1.97 |
Ventyx Biosciences Financials Summary
As of 31-Dec-2024, Ventyx Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (108,933) | (108,933) | (142,638) | 1,446,365 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (147,190) | (147,190) | (207,095) | (112,625) |
| Net Income | (135,122) | (135,122) | (192,962) | (108,426) |
| Total Assets | 276,563 | 276,563 | 277,693 | 371,400 |
| Total Debt | 10,794 | 10,794 | 12,506 | 1,558 |
Ventyx Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ventyx Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Ventyx Biosciences Comparisons
Industry
Financing
Details
Ventyx Biosciences Competitors (54)
One of Ventyx Biosciences’s 54 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Ventyx Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ventyx Biosciences Patents
Ventyx Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240010654-A1 | Crystalline forms of a tyk2 inhibitor | Pending | 06-Jul-2022 | ||
| EP-4054581-A1 | Tyk2 pseudokinase ligands | Pending | 08-Nov-2019 | ||
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as tyk2 pseudokinase ligands | Active | 08-Nov-2019 | ||
| US-20210139486-A1 | Tyk2 pseudokinase ligands | Active | 08-Nov-2019 | ||
| CA-3160637-A1 | Tyk2 pseudokinase ligands | Pending | 08-Nov-2019 | C07D487/04 |
Ventyx Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ventyx Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ventyx Biosciences Acquisitions (2)
Ventyx Biosciences’s most recent deal was a Merger/Acquisition with Zomagen Biosciences for . The deal was made on 09-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zomagen Biosciences | 09-Mar-2021 | Merger/Acquisition | Biotechnology | ||
| Oppilan Pharma | 01-Feb-2021 | Merger/Acquisition | Drug Discovery |
Ventyx Biosciences ESG
Risk Overview
Risk Rating
Updated September, 16, 2023
29.06 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Ventyx Biosciences FAQs
-
When was Ventyx Biosciences founded?
Ventyx Biosciences was founded in 2018.
-
Where is Ventyx Biosciences headquartered?
Ventyx Biosciences is headquartered in Encinitas, CA.
-
What is the size of Ventyx Biosciences?
Ventyx Biosciences has 85 total employees.
-
What industry is Ventyx Biosciences in?
Ventyx Biosciences’s primary industry is Drug Discovery.
-
Is Ventyx Biosciences a private or public company?
Ventyx Biosciences is a Public company.
-
What is Ventyx Biosciences’s stock symbol?
The ticker symbol for Ventyx Biosciences is VTYX.
-
What is the current stock price of Ventyx Biosciences?
As of 24-Mar-2025 the stock price of Ventyx Biosciences is $1.36.
-
What is the current market cap of Ventyx Biosciences?
The current market capitalization of Ventyx Biosciences is $96.7M.
-
Who are Ventyx Biosciences’s competitors?
Kite Pharma, NexImmune, TScan Therapeutics, Sorrento Therapeutics, and Ayala Pharmaceuticals are some of the 54 competitors of Ventyx Biosciences.
-
What is Ventyx Biosciences’s annual earnings per share (EPS)?
Ventyx Biosciences’s EPS for 12 months was -$1.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
